Karyopharm Expands Global Presence With European Subsidiary

Karyopharm Therapeutics Inc. KPTI, a clinical-stage pharmaceutical company, announced today that it has expanded its operational footprint with a wholly-owned European subsidiary and appointed Ran Frenkel, an international executive with significant experience managing European clinical operations and regulatory affairs activities within the biopharmaceutical industry, as Executive Vice President, Worldwide Clinical Development. Reporting to Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm, Mr. Frenkel will be responsible for managing the new subsidiary, Karyopharm Europe GmbH, which will be headquartered in Munich, Germany and will provide the corporate structure necessary to support Karyopharm's expanded clinical and regulatory activities in Europe. "The establishment of this European subsidiary will provide a strong base of clinical, medical and regulatory expertise to support our registration-directed clinical studies, which are being conducted primarily in Europe and the United States, as well as in Canada and other countries," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. "With a growing team in Europe and Ran at the helm, we have the resources and support to manage our current and planned clinical trials and to build additional European infrastructure as needed." Ran Frenkel has more than 20 years of experience in the international biopharmaceutical industry encompassing clinical, regulatory, business development and commercial operations activities. Prior to joining Karyopharm Europe GmbH, Mr. Frenkel held a number of senior management roles in Europe, Israel and the United States, most recently as Managing Director EMEA for Clinipace Worldwide, an international clinical research organization, where he had responsibility for the overall management of the organization in Europe, the Middle East and Africa. Prior to joining Clinipace Worldwide, Mr. Frenkel established and managed the Israeli office of PFC Pharma Focus AG, which was acquired by Clinipace in 2011, and he held the position of Managing Director at Actelion Pharmaceuticals with responsibility for all science and business affairs of the company in Israel.